- Title: Efficacy and safety of Etrasimod, an S1P1 modulator, in moderate to severe UC
- Study drug: Etrasimod
- Sponsor: Arena Pharmaceutical
- Participating centers and contact:
- InselSpital Bern
- PD Dr. med. Pascal Juillerat
- pascal.juillerat@insel.ch
- Target population: Moderate to severe UC
- Primary outcome:
- Proportion of Participants With Clinical Remission Assessed by Mayo Component Sub-scores [ Time Frame: Week 12 ]
- Proportion of Participants With Clinical Remission Assessed by Mayo Component Sub-scores [ Time Frame: Week 52 ]
- Inclusion criteria:
- Diagnosed with ulcerative colitis (UC) ≥ 3 months prior to screening
- Active UC confirmed by endoscopy
- Exclusion criteria:
- Severe extensive colitis
- Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD
- Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis
- More information: https://www.clinicaltrials.gov/ct2/show/NCT03945188?term=Etrasimod&cntry=CH&draw=2&rank=1